Fosrenol lanthanum carbonate: Phase IV data

Data from an open-label, active-controlled, Phase IV study in 2,520 ESRD patients with hyperphosphatemia showed that 12 weeks of Fosrenol treatment provided mean serum phosphorus control while signifi...